Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $34 price target.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga
Watsco, Inc. Enters into New $750.0 Million Credit Facility
Fintel2 Hours Ago
STX Stock Slips Despite Q1 Beat, Dividend Hike — Analyst Flags Slowing Margin Growth
Yahoo3 Hours Ago
Robinhood Stock And the Rate Trade Behind Short Term Bond ETF Demand
Yahoo3 Hours Ago
Waste Management, Inc. Announces Third Quarter 2026 Financial Results
Fintel3 Hours Ago
Cramer Says Micron Stock Does Whatever SK Hynix Does in Korea, and He Dislikes It
Yahoo3 Hours Ago
Alpaca · SIPUpdated October 27 17:37 NY15 Minutes Delayed
